Jan 10,2025
Suzhou Ribo Life Science and Ribocure AB are excited to share that we have achieved a key pre-clinical milestone in our siRNA programs, less than a year into our collaboration with Boehringer Ingelheim(click to view Boehringer Ingelheim's press news).
These achievements highlight the strength of Boehringer Ingelheim's expertise in MASH and validates the power of the Ribo platform and organization(click to view original news). We are looking forward to advancing these and remaining ourcollaboration programs into 2025 and beyond to address high unmet patient needs.
